BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36068197)

  • 1. Histone methyltransferase MLL1 drives renal tubular cell apoptosis by p53-dependent repression of E-cadherin during cisplatin-induced acute kidney injury.
    Zhang C; Guan Y; Zou J; Yang X; Bayliss G; Zhuang S
    Cell Death Dis; 2022 Sep; 13(9):770. PubMed ID: 36068197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of the mixed lineage leukemia 1-menin interaction aggravates acute kidney injury induced by folic acid and ischemia-reperfusion in mice.
    Hou X; Cui B; Qiu A; Liu N; Zhuang S
    Am J Physiol Renal Physiol; 2023 Nov; 325(5):F669-F680. PubMed ID: 37733875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
    Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
    Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA damage response in renal ischemia-reperfusion and ATP-depletion injury of renal tubular cells.
    Ma Z; Wei Q; Dong G; Huo Y; Dong Z
    Biochim Biophys Acta; 2014 Jul; 1842(7):1088-96. PubMed ID: 24726884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
    Pabla N; Huang S; Mi QS; Daniel R; Dong Z
    J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction.
    Ye X; Chen G; Jin J; Zhang B; Wang Y; Cai Z; Ye F
    Curr Med Chem; 2020; 27(33):5530-5542. PubMed ID: 31132972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression.
    Ni J; Hou X; Wang X; Shi Y; Xu L; Zheng X; Liu N; Qiu A; Zhuang S
    Cell Death Dis; 2019 May; 10(5):355. PubMed ID: 31043583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting MLL1-WDR5 interaction ameliorates neuropathic allodynia by attenuating histone H3 lysine 4 trimethylation-dependent spinal mGluR5 transcription.
    Lin TB; Lai CY; Hsieh MC; Ho YC; Wang HH; Yang PS; Cheng JK; Chen GD; Ng SC; Peng HY
    Pain; 2020 Sep; 161(9):1995-2009. PubMed ID: 32345914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
    Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
    J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
    Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
    Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
    Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
    J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice.
    Uehara M; Kusaba T; Ida T; Nakai K; Nakata T; Tomita A; Watanabe-Uehara N; Ikeda K; Kitani T; Yamashita N; Kirita Y; Matoba S; Humphreys BD; Tamagaki K
    Sci Rep; 2020 Mar; 10(1):4441. PubMed ID: 32157166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
    Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
    Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.
    Patel A; Vought VE; Swatkoski S; Viggiano S; Howard B; Dharmarajan V; Monteith KE; Kupakuwana G; Namitz KE; Shinsky SA; Cotter RJ; Cosgrove MS
    J Biol Chem; 2014 Jan; 289(2):868-84. PubMed ID: 24235145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of E-cadherin by PPBICA protects against cisplatin-induced acute kidney injury by attenuating inflammation and programmed cell death.
    Gao L; Liu MM; Zang HM; Ma QY; Yang Q; Jiang L; Ren GL; Li HD; Wu WF; Wang JN; Wei B; Liu XQ; Jiang C; Huang C; Li J; Meng XM
    Lab Invest; 2018 Jul; 98(7):911-923. PubMed ID: 29581579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of MLL1-menin interaction attenuates renal fibrosis in obstructive nephropathy.
    Zou J; Yu C; Zhang C; Guan Y; Zhang Y; Tolbert E; Zhang W; Zhao T; Bayliss G; Li X; Ye Z; Zhuang S
    FASEB J; 2023 Jan; 37(1):e22712. PubMed ID: 36527439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lethal (3) malignant brain tumor-like 2 (L3MBTL2) protein protects against kidney injury by inhibiting the DNA damage-p53-apoptosis pathway in renal tubular cells.
    Huang H; Xu C; Wang Y; Meng C; Liu W; Zhao Y; Huang XR; You W; Feng B; Zheng ZH; Huang Y; Lan HY; Qin J; Xia Y
    Kidney Int; 2018 Apr; 93(4):855-870. PubMed ID: 29276099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.
    Karatas H; Townsend EC; Bernard D; Dou Y; Wang S
    J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meclofenamic acid promotes cisplatin-induced acute kidney injury by inhibiting fat mass and obesity-associated protein-mediated m
    Zhou P; Wu M; Ye C; Xu Q; Wang L
    J Biol Chem; 2019 Nov; 294(45):16908-16917. PubMed ID: 31578283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.